DL-threo-PDMP hydrochloride
Based on 1 Customer Validation
DL-threo-PDMP hydrochloride is a competitive glucosylceramide synthase (GCS) inhibitor and antimalarial agent. DL-threo-PDMP hydrochloride competitively inhibits the activity of GCS. DL-threo-PDMP hydrochloride restores cisplatin sensitivity in cisplatin-resistant testicular germ cell tumor cells. DL-threo-PDMP hydrochloride blocks the growth of ring-stage Plasmodium falciparum parasites.
For research use only. We do not sell to patients.
- Purity: 99.40%
- CAS No.: 80938-69-8
- Formula: C23H39ClN2O3
- Molecular Weight:427.02
-
Storage:
-20°C, stored under nitrogen, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Anti-Infection Compound Library
HY-L002
-
Neuronal Signaling Compound Library
HY-L013
-
Anti-Cancer Compound Library
HY-L025
-
Endocrinology Compound Library
HY-L047
-
Antiparasitic Compound library
HY-L082
-
Lipid Metabolism Compound Library
HY-L091
-
Anti-Drug-Resistant Compound Library
HY-L169
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
MCE Bioactive Compound Library
HY-L001V
-
High-Throughput Bioactive Compound Library
HY-L205
All Parasite Isoforms
More
Biological Activity
|
Plasmodium |
DL-threo-PDMP (30 μmol/L; 48 h) hydrochloride restores cisplatin sensitivity in cisplatin-resistant SuSaR testicular germ cell tumor cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SuSaR (cisplatin-resistant human nonseminomatous testicular germ cell teratocarcinoma cell line)
-
Concentration:30 μmol/L (combined with cisplatin treatment)
-
Incubation Time:48 h (combined with cisplatin treatment)
-
Result:Reduced the cisplatin IC50 in SuSaR cells from 2.72 ± 0.16 μg/mL to 1.22 ± 0.22 μg/mL, resulting in 44.8% cisplatin resensitization.
Significantly increased intracellular ceramide levels in SuSaR cells compared to control, cisplatin alone, or DL-threo-PDMP alone.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice[1]
-
Dosage:50 mg/kg (single agent; combined with cisplatin 3.5 mg/kg)
-
Administration:i.p.; daily; 21 days; 1 hour before cisplatin (i.v.; once weekly; 3 consecutive weeks) for combined group
-
Result:Did not produce a significant reduction in tumor weight compared to vehicle-treated animals as a single agent.
Produced significant tumor weight reductions of 42.8% in TGT1XR tumors and 73.5% in TGT38XR tumors compared to vehicle controls when combined with cisplatin.
Induced a 2.7-fold increase in apoptotic cells (caspase-3 positive) in TGT1XR tumors and a 2.81-fold increase in TGT38XR tumors compared to cisplatin-only treatment when combined with cisplatin.
Chemical Information
-
CAS No. 80938-69-8
-
Appearance Solid
-
Molecular Weight 427.02
-
Formula C23H39ClN2O3
-
Color White to off-white
-
SMILES
O[C@H](C1=CC=CC=C1)[C@H](NC(CCCCCCCCC)=O)CN2CCOCC2.Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, stored under nitrogen, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
Solvent & Solubility
DMSO : 100 mg/mL (234.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Piulats JM, et al. Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent. Clin Cancer Res. 2018;24(15):3755-3766. [Content Brief]
[2]. Lauer SA, et al. Sphingolipid synthesis as a target for chemotherapy against malaria parasites. Proc Natl Acad Sci U S A. 1995;92(20):9181-9185. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3418 mL | 11.7091 mL | 23.4181 mL | 58.5453 mL |
| 5 mM | 0.4684 mL | 2.3418 mL | 4.6836 mL | 11.7091 mL | |
| 10 mM | 0.2342 mL | 1.1709 mL | 2.3418 mL | 5.8545 mL | |
| 15 mM | 0.1561 mL | 0.7806 mL | 1.5612 mL | 3.9030 mL | |
| 20 mM | 0.1171 mL | 0.5855 mL | 1.1709 mL | 2.9273 mL | |
| 25 mM | 0.0937 mL | 0.4684 mL | 0.9367 mL | 2.3418 mL | |
| 30 mM | 0.0781 mL | 0.3903 mL | 0.7806 mL | 1.9515 mL | |
| 40 mM | 0.0585 mL | 0.2927 mL | 0.5855 mL | 1.4636 mL | |
| 50 mM | 0.0468 mL | 0.2342 mL | 0.4684 mL | 1.1709 mL | |
| 60 mM | 0.0390 mL | 0.1952 mL | 0.3903 mL | 0.9758 mL | |
| 80 mM | 0.0293 mL | 0.1464 mL | 0.2927 mL | 0.7318 mL | |
| 100 mM | 0.0234 mL | 0.1171 mL | 0.2342 mL | 0.5855 mL |
DL-threo-PDMP hydrochloride Related Classifications
HY-116392B Related Classifications
Powered by Bioz
- DL-threo-PDMP
- 80938-69-8
- Glucosylceramide Synthase (GCS)
- Parasite
- cisplatin
- tubovesicular membrane network
- glucosylceramide synthase
- epithelial ovarian cancer
- sphingomyelin synthase
- nonseminomatous testicular germ cell tumors
- Plasmodium falciparum-infected erythrocytes
- cisplatin-resistant germline-derived orthoxenografts
- malaria
- Plasmodium falciparum ring-stage parasites
- Inhibitor
- inhibitor
- inhibit